Tamara B . Horwich

Learn More
Clyde W. Yancy, MD, MSc, FACC, FAHA Mariell Jessup, MD, FACC, FAHA Biykem Bozkurt, MD, PhD, FACC, FAHA Frederick A. Masoudi, MD, MSPH, FACC, FAHA Javed Butler, MBBS, FACC, FAHA Patrick E. McBride, MD, MPH, FACC Donald E. Casey, John J.V. McMurray, MD, FACC Mark H. Drazner, MD, MSc, FACC, FAHA Judith E. Mitchell, MD, FACC, FAHA Gregg C. Fonarow, MD, FACC,(More)
Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in five. Although promising evidence shows that the age-adjusted incidence of HF may have plateaued, HF still carries substantial morbidity and mortality, with 5-year(More)
OBJECTIVES The study aimed to evaluate the role of obesity in the prognosis of patients with heart failure (HF). BACKGROUND Previous reports link obesity to the development of HF. However, the impact of obesity in patients with established HF has not been studied. METHODS We analyzed 1,203 patients with advanced HF followed in a comprehensive HF(More)
OBJECTIVES This study aimed to evaluate the relationship between anemia and heart failure (HF) prognosis. BACKGROUND Although it is known that chronic diseases, including HF, may be associated with anemia, the impact of hemoglobin (Hb) level on symptoms and survival in HF has not been fully defined. We analyzed a cohort of 1,061 patients with advanced HF(More)
Traditional risk factors of a poor clinical outcome and mortality in the general population, including body mass index (BMI), serum cholesterol, and blood pressure (BP), are also found to relate to outcome in patients with chronic heart failure (CHF), but in an opposite direction. Obesity, hypercholesterolemia, and high values of BP have been demonstrated(More)
OBJECTIVES This study aimed to investigate the impact of hydroxymethylglutaryl coenzyme A reductase inhibitor (statin) therapy in patients with advanced heart failure (HF). BACKGROUND Although statins are known to reduce mortality in coronary artery disease (CAD), the impact of statin therapy in patients with HF has not been well studied. Both the(More)
In the general population, a high body mass index (BMI; in kg/m(2)) is associated with increased cardiovascular disease and all-cause mortality. However, the effect of overweight (BMI: 25-30) or obesity (BMI: >30) in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis (MHD) is paradoxically in the opposite direction; ie, a high(More)
BACKGROUND Cardiac troponin I (cTnI), a sensitive and specific marker of myocardial cell injury, is useful in diagnosing and assessing prognosis in acute coronary syndromes. Small studies report that cTnI is elevated in severe heart failure (HF) and may predict adverse outcomes. METHODS AND RESULTS The present study evaluated 238 patients with advanced HF(More)
B-type natriuretic peptide (BNP) and cardiac troponin (Tn) I or T have been demonstrated to provide prognostic information in patients with acute coronary syndromes. Whether admission BNP and Tn levels provide additive prognostic value in acutely decompensated heart failure (HF) has not been well studied. Hospitalizations for HF from April 2003 to December(More)
Currently, there are 5 million individuals with chronic heart failure (CHF) in the United States who have poor clinical outcomes, including high death rates. Observational studies have indicated a reverse epidemiology of traditional cardiovascular risk factors in CHF; in contrast to trends seen in the general population, obesity and hypercholesterolemia are(More)